Journal of Clinical Oncology
Articles in this Issue
Clinical factors associated with urinary morbidity in men undergoing combination prostate radiation therapy.
e17128 Background: The purpose of our investigation was to determine if pre-treatment factors could predict urinary morbidity after combination brachyther...
Evaluation of Bowhead health patient navigator for breast cancer treatment in India: A pilot study.
e13659 Background: Access to guideline-concordant cancer treatment is a significant challenge in India due to limited resources and variability in clinica...
The impact of immunotherapy versus chemotherapy on mortality and adverse events in cancer patients hospitalized with septic shock.
2653 Background: Traditionally, chemotherapies have been associated with well-characterized toxicity profiles and adverse events. Meanwhile, immune checkp...
Inpatient characteristics and outcomes of diffuse large B-cell lymphoma in adolescents and young adults.
e19042 Background: Diffuse large B-cell lymphoma (DLBCL) is the most commonly aggressive non-Hodgkin’s lymphoma known to also affect adolescents and young...
Real world utilization of comprehensive genomic profiling (CGP) in head and neck squamous cell carcinoma (SCCHN).
6021 Background: In Head and Neck Cancer, practice trends of utilizing comprehensive genomic profiling (CGP) vary depending on physician preference and te...
Payers’ perspectives on biosimilars in the US: Past, present, and future.
e13510 Background: With 10 blockbuster biologics facing patent expiration in the U.S. within the next five years, the oncology therapy area is poised for...
Risk of radiation necrosis with concurrent antibody-drug conjugates and radiotherapy in HER2-positive breast cancer with brain metastases: A meta-analysis.
1039 Background: Antibody-drug conjugates (ADCs) have transformed the outcomes of HER2-positive breast cancer (BC), particularly in patients with brain me...
MCM2 expression in locally advanced hormone receptor–positive HER2 negative (HR+/HER2-) early breast cancer receiving neoadjuvant chemotherapy.
e12532 Background: Mini-chromosome maintenance 2 (MCM2), a protein regulating the initiation of DNA replication, is associated with a high proliferative i...
A phase 1/2, open-label study evaluating the efficacy, safety, and pharmacokinetics of luveltamab tazevibulin in infants and children < 12 years of age with <i>CBFA2T3::GLIS2</i> acute myeloid leukemia.
TPS10074 Background: CBFA2T3::GLIS2 -rearranged acute myeloid leukemia (AML) is a rare subtype of AML occurring exclu...
Analysis immune-related of pembrolizumab adverse events based on the US FAERS database.
e24108 Background: Objective To introduce the risk of adverse events (AE) of pembrolizumab and provide a reference for the safe clinical application of th...
Clinical outcomes and treatment strategies of CDK4/6 inhibitors combined with endocrine therapy in HR-positive advanced breast cancer: A retrospective study from a single center.
e13072 Background: CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have emerged as a cornerstone treatment for hormone receptor-pos...
Communication skills training program for medical staff in cancer genomic testing: A mixed-methods assessment of an educational initiative.
9017 Background: Cancer genomic testing presents unique communication challenges for medical staff, particularly regarding...
Potent antitumor activity of the KRAS <sup>G12D</sup> inhibitor MRTX1133 in pancreatic cancer: Augmenting the nanoparticle-paclitaxel chemotherapy response.
e16358 Background: Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy with an extremely poor prognosis. The combination of nab-pac...
Ipilimumab and nivolumab after disease progression on single agent immunotherapy in mismatch repair deficient metastatic colorectal cancer.
e15523 Background: Pembrolizumab and ipilimumab with nivolumab (IPI/NIVO) are acceptable options for mismatch repair deficient (MMRd) metastatic colorecta...
Kaposi sarcoma herpesvirus (KSHV) subtypes and impact on survival in 107 patients with Kaposi sarcoma and other KSHV-associated diseases.
11532 Background: Kaposi sarcoma herpesvirus (KSHV, also known as human herpesvirus 8) is an oncogenic virus that causes Kaposi sarcoma (KS), one of the m...
Effectiveness and safety of sacituzumab govitecan in heavily pretreated metastatic HER2-negative breast cancer: A real-world multicenter analysis in China.
e13104 Background: Sacituzumab govitecan (SG) is the first antibody-drug conjugate targeting trophoblast cell - surface antigen 2 (Trop-2). Clinical trial...
Integration of cfDNA fragmentomics for early biliary tract cancer detection.
4131 Background: Biliary Tract Cancer (BTC) is a highly aggressive malignancy with poor survival outcomes, primarily due to the lack of effective early de...
A phase 2, open-label, randomized study of livmoniplimab in combination with budigalimab versus chemotherapy in patients with metastatic urothelial carcinoma.
TPS4618 Background: Urothelial carcinoma (UC) has a high mortality rate in patients (pts) with metastatic disease. While immune checkpoint inhibitors (CPI...
Small nucleolar RNAs (snoRNAs) expression and effects on patient (pt) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB (Alliance)/SWOG 80405.
3145 Background: SnoRNAs are non-coding RNAs that primarily guide the chemical modification of ribosomal RNA. Emerging evidence suggests snoRNAs play crit...
A phase 1/2 study of FOG-001, a first-in-class direct β-catenin: TCF inhibitor, in patients with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors.
TPS3169 Background: Activation of the Wnt/β-catenin pathway, often as truncal APC mutations, in 80–90% of CRCs and other solid tumors, is known to be a ke...
Maintenance therapy with azacitidine and valproic acid after allogeneic stem cell transplant in patients with high-risk myelodysplastic syndrome and acute myelogenous leukemia.
6578 Background: Relapse is a major cause of death after allogeneic stem cell transplant (allo-SCT) in patients with high-risk myelodysplastic syndrome (M...
Treatment beyond progression and rechallenge with pyrotinib in HER2-positive metastatic breast cancer and brain metastases: A multicenter real-world study.
e13005 Background: Despite advances in treatment, patients with HER2-positive metastatic breast cancer (MBC) continue to face the challenge of drug resist...
Palbociclib in patients (pts) with ovarian cancer (OC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
e17660 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers w...
Accelerator-based boron neutron capture therapy, a randomized controlled trial for refractory recurrent high-grade meningiomas.
2083 Background: High-grade meningiomas (HGMs) recurred after X-ray treatment showed pessimistic prognosis. We conducted “A phase II investigator-lead RCT...
A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36).
TPS8669 Background: Minimally invasive analyses of circulating cell-free tumor DNA (ctDNA) have shown clinical value as an early endpoint of immunotherapy...